Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000
Financing Transaction: Cingulate Inc. has secured $5 million through a non-convertible, unsecured promissory note to fund working capital and corporate purposes, with plans to support clinical and regulatory activities until late 2025.
Company Overview: Cingulate is a biopharmaceutical company focused on developing next-generation pharmaceutical products using its Precision Timed Release™ technology, initially targeting ADHD treatment and exploring other therapeutic areas like anxiety disorders.
Trade with 70% Backtested Accuracy
Analyst Views on CING
About CING
About the author
Cingulate Reports Slight Increase in Q4 Net Loss
- Financial Performance: Cingulate reported a net loss of $6.3 million for Q4 2025, slightly up from $6.2 million in Q4 2024, indicating ongoing challenges in achieving profitability.
- Cash Flow Status: As of December 31, 2025, Cingulate had approximately $11.0 million in cash and cash equivalents, a decrease of $1.3 million from the previous year, reflecting pressure on the company's liquidity management.
- Working Capital Changes: The reduction in working capital may impact the company's future investment capabilities and operational flexibility, particularly in research and development and marketing efforts.
- Market Reaction: Despite the lack of significant improvement in financial data, investors remain cautiously optimistic about Cingulate's long-term potential, which may influence its stock price performance.
Cingulate's ADHD Drug Patent Approved by USPTO
- Patent Approval: The USPTO has approved Cingulate's ADHD drug patent application filed in November 2023, marking a significant advancement in the company's neurological treatment technologies and expected to provide crucial support for an upcoming regulatory decision.
- Technological Innovation: The patent covers the 'Trimodal, Precision-Timed Pulsatile Release Tablet' technology, which releases medication at multiple timed intervals throughout the day, aiming to address common issues with stimulant medications, thereby enhancing patient experience.
- Positive Market Reaction: Following the patent approval, Cingulate's shares jumped over 4% in pre-market trading on Sunday, reflecting investor optimism about the company's future, especially in light of the impending FDA decision.
- Successful Clinical Trials: Before submitting the New Drug Application, Cingulate completed Phase 3 trials in both adult and pediatric patients, demonstrating significant improvements in ADHD symptoms, which further bolsters market confidence in its product.
Biotech Stocks Surge: Coherus Up 9.09% in After-Hours Trading
- Coherus Performance: Coherus Oncology, Inc. (CHRS) rose 9.09% in after-hours trading, closing at $1.73 with a $0.14 gain, indicating strong investor confidence in its future prospects.
- Sensei Biotech Surge: Sensei Biotherapeutics, Inc. (SNSE) surged 10.06% after hours, finishing at $12.47 with a $1.14 increase, reflecting positive market expectations for its products.
- uniQure Significant Jump: uniQure N.V. (QURE) posted a 9.96% rise in after-hours trading, closing at $24.95 with a $2.26 gain, suggesting investor optimism regarding its R&D progress.
- IO Biotech Strategic Exploration: Although IO Biotech, Inc. (IOBT) had no fresh news on Thursday, its stock still gained 4.19%, closing at $0.50, indicating market interest in its exploration of strategic alternatives, including potential mergers or asset sales.
Roth Capital Reaffirms Buy Rating on Cingulate, Reduces Price Target to $16
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.
INBX Rises 81% Following Study Results; FEMY, CING, CYH Surge in After-Hours Trading
Inhibrx Biosciences Surge: Inhibrx Biosciences (INBX) shares soared over 81% after positive Phase 2 trial results for ozekibart in treating advanced chondrosarcoma, alongside updates on other cancer treatment studies.
Femasys Gains: Femasys Inc. (FEMY) saw an 18% increase following the launch of a post-market clinical study for its FemBloc Permanent Birth Control, complying with EU regulations.
Cingulate's Presentation: Cingulate Inc. (CING) rose over 6% after announcing that data from its ADHD treatment candidate, CTx-1301, will be presented at the AACAP Annual Meeting, highlighting its potential in ADHD management.
Community Health Systems Performance: Community Health Systems, Inc. (CYH) shares increased over 4% after reporting positive Q3 results, contributing to a generally favorable after-hours trading environment for biotech stocks.
Cingulate's Top ADHD Candidate CTx-1301 Chosen for Podium Presentation at AACAP Annual Meeting
CTx-1301 Presentation: Cingulate Inc. announced that data from its ADHD candidate CTx-1301 will be presented at the AACAP Annual Meeting, highlighting its once-daily, extended-release formulation aimed at improving treatment for ADHD patients.
Expert Presentation: Dr. Ann Childress, a leading ADHD specialist, will present the Phase 3 trial results, emphasizing CTx-1301's efficacy and safety in pediatric subjects with ADHD.
Innovative Drug Delivery: CTx-1301 utilizes Cingulate's Precision Timed Release™ platform to provide three timed releases of medication throughout the day, addressing limitations of current stimulant therapies.
Company Overview: Cingulate Inc. is focused on developing next-generation pharmaceutical products to enhance patient outcomes, with CTx-1301 in late-stage development for ADHD and other candidates targeting anxiety and neuropsychiatric conditions.
Cingulate Reports Slight Increase in Q4 Net Loss
- Financial Performance: Cingulate reported a net loss of $6.3 million for Q4 2025, slightly up from $6.2 million in Q4 2024, indicating ongoing challenges in achieving profitability.
- Cash Flow Status: As of December 31, 2025, Cingulate had approximately $11.0 million in cash and cash equivalents, a decrease of $1.3 million from the previous year, reflecting pressure on the company's liquidity management.
- Working Capital Changes: The reduction in working capital may impact the company's future investment capabilities and operational flexibility, particularly in research and development and marketing efforts.
- Market Reaction: Despite the lack of significant improvement in financial data, investors remain cautiously optimistic about Cingulate's long-term potential, which may influence its stock price performance.
Cingulate's ADHD Drug Patent Approved by USPTO
- Patent Approval: The USPTO has approved Cingulate's ADHD drug patent application filed in November 2023, marking a significant advancement in the company's neurological treatment technologies and expected to provide crucial support for an upcoming regulatory decision.
- Technological Innovation: The patent covers the 'Trimodal, Precision-Timed Pulsatile Release Tablet' technology, which releases medication at multiple timed intervals throughout the day, aiming to address common issues with stimulant medications, thereby enhancing patient experience.
- Positive Market Reaction: Following the patent approval, Cingulate's shares jumped over 4% in pre-market trading on Sunday, reflecting investor optimism about the company's future, especially in light of the impending FDA decision.
- Successful Clinical Trials: Before submitting the New Drug Application, Cingulate completed Phase 3 trials in both adult and pediatric patients, demonstrating significant improvements in ADHD symptoms, which further bolsters market confidence in its product.
Biotech Stocks Surge: Coherus Up 9.09% in After-Hours Trading
- Coherus Performance: Coherus Oncology, Inc. (CHRS) rose 9.09% in after-hours trading, closing at $1.73 with a $0.14 gain, indicating strong investor confidence in its future prospects.
- Sensei Biotech Surge: Sensei Biotherapeutics, Inc. (SNSE) surged 10.06% after hours, finishing at $12.47 with a $1.14 increase, reflecting positive market expectations for its products.
- uniQure Significant Jump: uniQure N.V. (QURE) posted a 9.96% rise in after-hours trading, closing at $24.95 with a $2.26 gain, suggesting investor optimism regarding its R&D progress.
- IO Biotech Strategic Exploration: Although IO Biotech, Inc. (IOBT) had no fresh news on Thursday, its stock still gained 4.19%, closing at $0.50, indicating market interest in its exploration of strategic alternatives, including potential mergers or asset sales.
Roth Capital Reaffirms Buy Rating on Cingulate, Reduces Price Target to $16
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.
INBX Rises 81% Following Study Results; FEMY, CING, CYH Surge in After-Hours Trading
Inhibrx Biosciences Surge: Inhibrx Biosciences (INBX) shares soared over 81% after positive Phase 2 trial results for ozekibart in treating advanced chondrosarcoma, alongside updates on other cancer treatment studies.
Femasys Gains: Femasys Inc. (FEMY) saw an 18% increase following the launch of a post-market clinical study for its FemBloc Permanent Birth Control, complying with EU regulations.
Cingulate's Presentation: Cingulate Inc. (CING) rose over 6% after announcing that data from its ADHD treatment candidate, CTx-1301, will be presented at the AACAP Annual Meeting, highlighting its potential in ADHD management.
Community Health Systems Performance: Community Health Systems, Inc. (CYH) shares increased over 4% after reporting positive Q3 results, contributing to a generally favorable after-hours trading environment for biotech stocks.
Cingulate's Top ADHD Candidate CTx-1301 Chosen for Podium Presentation at AACAP Annual Meeting
CTx-1301 Presentation: Cingulate Inc. announced that data from its ADHD candidate CTx-1301 will be presented at the AACAP Annual Meeting, highlighting its once-daily, extended-release formulation aimed at improving treatment for ADHD patients.
Expert Presentation: Dr. Ann Childress, a leading ADHD specialist, will present the Phase 3 trial results, emphasizing CTx-1301's efficacy and safety in pediatric subjects with ADHD.
Innovative Drug Delivery: CTx-1301 utilizes Cingulate's Precision Timed Release™ platform to provide three timed releases of medication throughout the day, addressing limitations of current stimulant therapies.
Company Overview: Cingulate Inc. is focused on developing next-generation pharmaceutical products to enhance patient outcomes, with CTx-1301 in late-stage development for ADHD and other candidates targeting anxiety and neuropsychiatric conditions.
